By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...
A groundbreaking multi-stakeholder report reveals that transitioning to Non-Animal Methods (NAMs) can reduce drug development ...
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...
As India’s pharmaceutical industry moves towards becoming a 500 billion dollars global powerhouse by 2047, a new report ...
In a year from now, progress is to be measured in the institutionalisation of the approach with greater regulatory acceptance ...
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...
A major step toward simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to ...
Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...
New treatments based on biological molecules like RNA give scientists unprecedented control over how cells function. But ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results